P62-mediated mitophagy inducer (PMI) is a regulator of mitophagy .

TRAF6 peptide, a specific TRAF6-p62 inhibitor, effectively inhibits NGF-dependent TrkA ubiquitination, showcasing strong research potential for neurological conditions including Alzheimer's disease (AD), Parkinson's, ALS, head trauma, epilepsy, and stroke [1].

ML162 is an inhibitor of GPX4 that is selectively lethal to mutant RAS oncogene-expressing cell lines (IC50s = 25 and 578 nM for HRASG12V-expressing and wild-type BJ fibroblasts, respectively)

TRAF6 peptide TFA, a specific inhibitor of the TRAF6-p62 interaction, significantly inhibits NGF-dependent ubiquitination of TrkA. This peptide demonstrates promising research applications in various neurological disorders, including Alzheimer's disease (AD), Parkinson's, ALS, head trauma, epilepsy, and stroke [1].

K67 is a specific inhibitor against the interaction between KEAP1 DC domain and S349-phosphorylated KIR of p62/SQSTM1.

Dusquetide (SGX942) TFA, a first-in-class innate defense regulator (IDR), modulates the innate immune response to pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) by interacting with p62. This compound is effective in both diminishing inflammation and enhancing the elimination of bacterial infections [1].

TrxR-IN-3 (Compound 2c) is a effective TrxR inhibitor. TrxR-IN-3 shows strong antiproliferative activities against five human cancer cell lines, especially against breast tumor cells. TrxR-IN-3 increases ROS levels and leads to significant apoptosis by regulating the expression of apoptosis-related proteins in the breast cancer cells. TrxR-IN-3 also triggers the formation of autophagosomes and autolysosomes by promoting the expression of LC3-II and Beclin-1 and reducing the expression of LC3-I and p62 proteins [1].

XRK3F2 is an inhibitor of the p62-ZZ domain, blunts MM-induced Runx2 suppression in vitro, and induces new bone formation and remodeling in the presence of tumor in vivo.

XIE62-1004 is a chemical compound that induces the interaction between p62 and LC3 by binding to the ZZ domain of p62. This interaction promotes p62 self-aggregation and its subsequent interaction with LC3 on autophagosome membranes, thereby facilitating the delivery of cargo proteins to the autophagosome for degradation. XIE62-1004 is effective both in vitro and in vivo, displaying specificity for the wild type of p62 and exhibiting its actions in a concentration- and time-dependent manner. Additionally, it induces the degradation of mutant huntingtin in vitro and can be employed in AUTAC protein degradation systems to trigger autophagy via p62 self-aggregation and LC3 interaction.

Dusquetide TFA is a kind of innate defense regulator (IDR).Dusquetide TFA has been shown to be active in reducing inflammation and increasing clearance of bacterial infections.Dusquetide TFA regulates innate immune responses to PAMPs and DAMPs in combinat

Antitumor agent-81, a P62-RNF168 agonist with low cytotoxicity, enhances the P62-RNF168 interaction, leading to decreased RNF168-mediated H2A ubiquitination and impaired homologous recombination-mediated DNA repair. Additionally, it exhibits dose-dependent inhibition of xenograft tumor growth in mice.